GeoVax Labs (GOVX) vs Oragenics (OGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
GeoVax Labs is the larger company by market cap ($985,459 vs $708,377), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GOVX | OGEN |
|---|---|---|
| Share price | $1.81 | $0.157 |
| Market cap | $985.46K | $708.38K |
| 1-day change | -5.24% | -8.72% |
| EPS (TTM) | $-15.03 | $-1.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.49M | — |
| Revenue growth (YoY) | -37.06% | — |
| Net income (latest FY) | $-21.46M | $-9.84M |
| Operating margin | -869.34% | — |
| Net margin | -862.34% | — |
| 52-week high | $270.60 | $1.11 |
| 52-week low | $1.51 | $0.13 |
| Distance from 52-week high | -99.33% | -85.86% |
| Analyst consensus | none | — |
| Avg. price target upside | +452.49% | — |
| Average volume | 213.41K | 849.30K |
| Shares outstanding | 544.45K | 4.51M |
| Employees | 19 | 3 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About GeoVax Labs
GOVX stock →GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Oragenics
OGEN stock →Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
GOVX vs OGEN FAQ
Which is bigger, GeoVax Labs or Oragenics?
GeoVax Labs (GOVX) is larger, with a market capitalization of $985.46K compared with $708.38K for Oragenics (OGEN).
Are GeoVax Labs and Oragenics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.